Novo Nordisk's recent Capital Markets Day, led by CEO Mike Doustdar, left investors underwhelmed despite the company's ambitious targets. The Danish drugmaker announced plans to launch more than five "multi-blockbuster" drugs by 2030 and generate over 150 billion Danish kroner (approximately $23 billion) in pipeline sales by 2035. However, shares fell as much as 7.7% following the presentation, indicating that investors had already priced in similar growth expectations, with BMO Capital Markets noting that Novo's estimated compound annual growth rate (CAGR) of 3.53% was slightly below the anticipated 3.65%.
A key concern for investors is the impending patent expiration for semaglutide, the active ingredient in Wegovy and Ozempic, which accounts for over half of Novo's sales, with the U.S. patent expiring in 2032. Analysts and investors urged Doustdar to outline a more concrete strategy for diversification beyond obesity and diabetes drugs, suggesting a greater appetite for bolt-on acquisitions or licensing deals rather than relying solely on internal R&D. Doustdar did promise more active business development, stating the company would be "shopping" for opportunities in blood and endocrine disorders, liver diseases, and cardiovascular disease, aiming for five new Phase 3 launches in these areas alongside five in obesity and diabetes within the next decade.
Despite the successful launch of the Wegovy pill, which has reached 7 million prescriptions and is considered the best U.S. product launch by volume, Novo Nordisk is facing intense competition from Eli Lilly. Lilly's tirzepatide franchise continues to gain market share from Ozempic and Wegovy. Furthermore, Novo's future offerings, such as CagriSema, have shown less impressive results compared to Lilly's tirzepatide in some trials, particularly for weight loss in Type 2 Diabetes patients. The approval for CagriSema in Type 2 Diabetes is not expected until 2028, after key outcomes data are available in late 2027. Novo's cardiovascular ambitions also suffered a setback with the failure of the Phase 3 Zeus trial for ziltivekimab, and the subsequent discontinuation of two more late-stage studies for the IL-6 inhibitor, raising questions about the target's validity in chronic cardiovascular disease.
Investors had hoped for a more robust plan to counter the competitive landscape and patent cliffs. While Novo Nordisk presented a vision for future growth and diversification, the market's reaction suggests that the proposed strategy was not sufficiently differentiated or aggressive enough to alleviate concerns about its long-term prospects beyond its current blockbuster weight-loss drugs. The company's pledge to achieve $23 billion in pipeline sales by 2035 did not prevent a significant drop in its stock price, indicating a desire for more immediate and impactful strategic shifts.
